Proposal to move guidance to the static list

The planned date for review of the above guidance is November 2012.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

Since the publication of TA184, there has been no significant change in the evidence that would necessitate an update of the recommendations in the existing guidance.  The patent for intravenous topotecan has expired since TA184 was published and generic formulations are now available, but this is not likely to affect the current recommendations for intravenous topotecan.  Consequently we propose that the original guidance become static.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial.  Please see appendix A for a full list of the organisations we have contacted. 

November 2012